Efficacy, Safety And Dosage Of Afatinib In Patients With Non-Small Cell Lung Cancer After Failure Of Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-Tki)

被引：0
|
作者：
Park, C. [1 ]
Kim, T. [1 ]
Shin, H. [2 ]
Ban, H. [2 ]
Lim, J. [1 ]
Kwon, Y. [2 ]
Oh, I. [1 ]
Kim, Y. [1 ,2 ]
Lim, S. [2 ]
Kim, Y. [1 ,2 ]
机构：
[1] Chonnam Natl Univ, Hwasun Hosp, Hawsun, Jeonnam, South Korea
[2] Chonnam Natl Univ Hosp, Gwangju, South Korea
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
lung cancer; EGFR; afatinib;
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6676
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
    Kanaji, Nobuhiro
    Ichihara, Eiki
    Tanaka, Takaaki
    Ninomiya, Takashi
    Kozuki, Toshiyuki
    Ishikawa, Nobuhisa
    Nishii, Kazuya
    Shoda, Hiroyasu
    Yamaguchi, Kakuhiro
    Kawakado, Keita
    Toyoda, Yuko
    Inoue, Masaaki
    Miyatake, Nobuyuki
    Watanabe, Naoki
    Inoue, Takuya
    Mizoguchi, Hitoshi
    Komori, Yuta
    Kojima, Kazuki
    Kadowaki, Norimitsu
    LUNG, 2024, 202 (01) : 63 - 72
  • [32] Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
    Nobuhiro Kanaji
    Eiki Ichihara
    Takaaki Tanaka
    Takashi Ninomiya
    Toshiyuki Kozuki
    Nobuhisa Ishikawa
    Kazuya Nishii
    Hiroyasu Shoda
    Kakuhiro Yamaguchi
    Keita Kawakado
    Yuko Toyoda
    Masaaki Inoue
    Nobuyuki Miyatake
    Naoki Watanabe
    Takuya Inoue
    Hitoshi Mizoguchi
    Yuta Komori
    Kazuki Kojima
    Norimitsu Kadowaki
    Lung, 2024, 202 : 63 - 72
  • [33] A PILOT STUDY OF A STEROID SULPHATASE INHIBITOR (BN83495) IN PATIENTS WITH RASH DUE TO TREATMENT WITH AN ORAL EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) FOR NON-SMALL CELL LUNG CANCER (NSCLC)
    Mileshkin, Linda
    Mccormack, Chris
    Michael, Michael
    Solomon, Ben
    Urban, Damien
    Link, Emma
    Cowan, Linda
    Zalcberg, John
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1020 - S1020
  • [34] Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer
    Noda, Shoko
    Kanda, Shintaro
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (05) : 547 - 556
  • [35] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
    Kris, MG
    Natale, RB
    Herbst, RS
    Lynch, TJ
    Prager, D
    Belani, CP
    Schiller, JH
    Kelly, K
    Spiridonidis, H
    Sandler, A
    Albain, KS
    Cella, D
    Wolf, MK
    Averbuch, SD
    Ochs, JJ
    Kay, AC
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16): : 2149 - 2158
  • [36] FDG PET/CT versus CT in Predicting Histopathological Response to Epidermal Growth Factor Receptor: Tyrosine-kinase Inhibitor (EGFR-TKI) Treatment in Resectable Non-small Cell Lung Cancer
    Aukema, T.
    Van Gool, M.
    Schaake, E.
    Kappers, I.
    Codrington, H.
    Olmos, R. Valdes
    Teertstra, J.
    Van Pel, R.
    Burgers, S.
    Van Tinteren, H.
    Klomp, H.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S35 - S35
  • [37] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
    Morin-Ben Abdallah, Sami
    Hirsh, Vera
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [38] Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure
    Kawamura, Takahisa
    Kenmotsu, Hirotsugu
    Taira, Tetsuhiko
    Omori, Shota
    Nakashima, Kazuhisa
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Mori, Keita
    Nakajima, Takashi
    Ohde, Yasuhisa
    Endo, Masahiro
    Takahashi, Toshiaki
    CANCER SCIENCE, 2016, 107 (07) : 1001 - 1005
  • [39] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S873 - S873
  • [40] Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI
    Lin, Liping
    Zhao, Juanjuan
    Hu, Jiazhu
    Huang, Fuxi
    Han, Jianjun
    He, Yan
    Cao, Xiaolong
    JOURNAL OF CANCER, 2018, 9 (03): : 528 - 534
12345